Practical Tips

Two studies from 2016 and 80 oncology patients: what was really measured, with what scales, at what point in time, and what these results do not resolve.

The 5-HT2A receptor is the entry point for classic psychedelics. Check what the experiment with ketanserin showed and how neuroplasticity arises.

What are psychoplastogens, how psychedelics bind to the TrkB receptor, and what this changes in the understanding of depression. A review of studies from Nature Neuroscience and Science.

The Default Mode Network (DMN) and afterglow: what was really measured in studies on psilocybin, how long the effects lasted, and what was not shown.

Phase 3 studies on MDMA, the FDA refusal from 2024, and pilot studies with psilocybin in veterans. How many people, what numbers, and how many veterans were actually in these trials.

Pharmacokinetics, the 5-HT2A receptor, and the cycle: what studies on psychedelics say about women, and what no one has published yet despite common belief.

The Israeli medical marijuana program: over 137 thousand patients, beginnings in the 90s, research results on chronic pain, and decriminalization rules.

How to keep a cannabinoid journal: what to record in each entry, why to note milligrams instead of drops, and what studies say about the impact of meals.

Mustiness, ammonia, or a matte coating on the flower. How to recognize mold, over-drying, and old cannabis, and what smell will never detect.

Anandamide is an endocannabinoid discovered in 1992. Check how it binds to CB1, why it disappears after a few minutes, and what actually raises its level.